GAVRETO® is the commercial brand name of Pralsetinib Capsules, an orally active, highly selective rearranged during transfection (RET) inhibitor developed by Blueprint Medicines and licensed to BeiGene. It exerts anti-tumor activity by specifically inhibiting the kinase activity of RET, thereby…
VITRAKVI® is the commercial brand name of Larotrectinib Sulfate Capsules, a highly selective tropomyosin receptor kinase (TRK) inhibitor developed by Bayer. It exerts anti-tumor activity by specifically inhibiting the kinase activity of tropomyosin receptor kinases (TRKA, TRKB, TRKC) encoded by…
LENVIMA® is the commercial brand name of Lenvatinib Mesilate Capsules, an orally active, multi-targeted tyrosine kinase inhibitor (TKI) developed by Eisai. It exerts anti-tumor activity by inhibiting multiple receptor tyrosine kinases, including VEGFR, FGFR, PDGFR, RET, and KIT, thereby suppressing…
Rozlytrek® is the commercial brand name of Entrectinib Capsules, an orally active, highly selective tropomyosin receptor kinase (TRK) and ROS1 inhibitor developed by Roche. It exerts anti-tumor activity by inhibiting the kinase activity of TRK and ROS1, thereby blocking downstream…
CALQUENCE® is the commercial brand name of Acalabrutinib Capsules, a highly selective, irreversible second-generation Bruton tyrosine kinase (BTK) inhibitor developed by AstraZeneca. It exerts anti-tumor activity by covalently binding to BTK, thereby inhibiting B-cell receptor signaling and blocking the proliferation…
IBRANCE® is the commercial brand name of Palbociclib Capsules, a first-in-class, orally active cyclin-dependent kinase 4/6 (CDK4/6) inhibitor developed by Pfizer. It exerts anti-tumor activity by selectively inhibiting CDK4/6, thereby blocking the phosphorylation of the retinoblastoma (Rb) protein, arresting the…
KOSELUGO® is the commercial brand name of Selumetinib Hydrogen Sulfate Capsules, an oral, selective mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor developed by AstraZeneca. It exerts its therapeutic effect by blocking the abnormal activation of the RAS/RAF/MEK/ERK signaling pathway, thereby…
ZYKADIA® is the commercial brand name of Ceritinib Capsules, a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor developed by Novartis. It exerts anti-tumor activity by selectively inhibiting the kinase activity of ALK, thereby blocking downstream signaling pathways and suppressing…
XALKORI® is the commercial brand name of Crizotinib Capsules, a first-generation anaplastic lymphoma kinase (ALK) and c-MET/ROS1 tyrosine kinase inhibitor developed by Pfizer. It exerts anti-tumor activity by selectively inhibiting the kinase activity of ALK, ROS1 and c-MET, thereby blocking…
Tafinlar® is the commercial brand name of Dabrafenib Mesylate Capsules, a selective BRAF kinase inhibitor developed by Novartis. It exerts anti-tumor activity by specifically inhibiting the mutated BRAF protein (BRAF V600E/V600K), thereby blocking the aberrant activation of the MAPK signaling…